Skip to content


GLOW Study

Tarcocimab tedromer
Once every 6 months after 3 initiating doses

Compared to:


About the GLOW Study in Non-proliferative Diabetic Retinopathy

The Phase 3 GLOW study is a global, multi-center, randomized
pivotal superiority study designed to evaluate the efficacy and
safety of tarcocimab tedromer in approximately 240 patients
with treatment-naïve, moderately severe to severe
non-proliferative diabetic retinopathy (NPDR). Patients are
randomized to receive either tarcocimab tedromer every six
months after initiating doses given at baseline, 8 weeks and 20
weeks into the study, or to receive sham injections. The
primary endpoint is at one year and patients will be treated
and followed for two years. Outcomes include changes in
diabetic retinopathy severity, measured on a standardized
photographic grading scale, and the rate of development of
sight-threatening complications due to diabetic retinopathy.
We believe tarcocimab tedromer has the potential to be the
longest-interval intravitreal therapeutic option for patients
with diabetic retinopathy. Additional information about GLOW
(also called Study KS301P106) can be found on under Trial Identifier NCT05066230